NZ603161A - Superior efficacy of cd37 antibodies in cll blood samples - Google Patents

Superior efficacy of cd37 antibodies in cll blood samples

Info

Publication number
NZ603161A
NZ603161A NZ603161A NZ60316111A NZ603161A NZ 603161 A NZ603161 A NZ 603161A NZ 603161 A NZ603161 A NZ 603161A NZ 60316111 A NZ60316111 A NZ 60316111A NZ 603161 A NZ603161 A NZ 603161A
Authority
NZ
New Zealand
Prior art keywords
cells
antibodies
population
antibody
blood samples
Prior art date
Application number
NZ603161A
Other languages
English (en)
Inventor
Karl-Heinz Heider
Stephan Stilgenbauer
Thorsten Zenz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ603161(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Priority to NZ703225A priority Critical patent/NZ703225A/en
Publication of NZ603161A publication Critical patent/NZ603161A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ603161A 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples NZ603161A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ703225A NZ703225A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (1)

Publication Number Publication Date
NZ603161A true NZ603161A (en) 2015-02-27

Family

ID=44546328

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ603161A NZ603161A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples
NZ703225A NZ703225A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ703225A NZ703225A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Country Status (15)

Country Link
US (3) US20120189618A1 (enExample)
EP (2) EP2593479A1 (enExample)
JP (2) JP2013538790A (enExample)
KR (1) KR20130100918A (enExample)
CN (2) CN105749276A (enExample)
AU (1) AU2011278227B2 (enExample)
BR (1) BR112013001012A2 (enExample)
CA (1) CA2799036A1 (enExample)
CL (1) CL2013000101A1 (enExample)
EA (1) EA025365B1 (enExample)
IL (1) IL222775A (enExample)
MX (1) MX341463B (enExample)
NZ (2) NZ603161A (enExample)
PH (1) PH12013500118A1 (enExample)
WO (1) WO2012007576A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
JP2015517511A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
AU2016248947B2 (en) 2015-04-13 2020-07-16 Pfizer Inc. Chimeric Antigen Receptors targeting B-Cell Maturation Antigen
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN110461363B (zh) * 2017-03-16 2024-04-02 综合医院公司 靶向cd37的嵌合抗原受体
IL269645B2 (en) 2017-03-31 2025-05-01 Genmab Holding B V Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
WO2020070313A1 (en) 2018-10-04 2020-04-09 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
WO2025083205A1 (en) 2023-10-18 2025-04-24 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
WO2009023386A2 (en) * 2007-07-06 2009-02-19 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
AU2009234277B2 (en) * 2008-04-11 2014-12-04 Aptevo Research And Development Llc CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP2358390A1 (en) * 2008-11-13 2011-08-24 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic combination therapies and uses thereof

Also Published As

Publication number Publication date
KR20130100918A (ko) 2013-09-12
CN103003309A (zh) 2013-03-27
EA025365B1 (ru) 2016-12-30
JP2013538790A (ja) 2013-10-17
PH12013500118A1 (en) 2013-03-11
CA2799036A1 (en) 2012-01-19
CN105749276A (zh) 2016-07-13
US20150266967A1 (en) 2015-09-24
IL222775A0 (en) 2012-12-31
CL2013000101A1 (es) 2013-12-27
EP2593479A1 (en) 2013-05-22
AU2011278227A1 (en) 2012-11-15
WO2012007576A1 (en) 2012-01-19
EP3252077A1 (en) 2017-12-06
MX341463B (es) 2016-08-22
IL222775A (en) 2017-10-31
BR112013001012A2 (pt) 2016-05-24
AU2011278227B2 (en) 2017-03-02
NZ703225A (en) 2016-11-25
JP2017019800A (ja) 2017-01-26
EA201201660A1 (ru) 2013-07-30
US20130236454A1 (en) 2013-09-12
US20120189618A1 (en) 2012-07-26
MX2012013613A (es) 2012-12-17

Similar Documents

Publication Publication Date Title
NZ603161A (en) Superior efficacy of cd37 antibodies in cll blood samples
US20220241347A1 (en) Placenta-derived adherent cell exosomes and uses thereof
NZ594055A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2013120012A3 (en) Cdim binding proteins and uses thereof
EA200971056A1 (ru) ПРОДУЦИРОВАНИЕ РЕКОМБИНАНТНЫХ БЕЛКОВ В КЛЕТКАХ ПТИЦ Еbx®
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
NZ723369A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2009008843A (es) Peptidomimeticos fijados a un patron.
MX340017B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2534564C3 (ru) Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2012153218A (ru) Пептиды, проникающие в клетки, и их применения
NZ582150A (en) Antibodies to human programmed death receptor pd-1
NZ610091A (en) Antibodies
Shen et al. Systemic delivery of mPEG‐masked trispecific T‐cell nanoengagers in synergy with STING agonists overcomes immunotherapy resistance in TNBC and generates a vaccination effect
JP2012505665A5 (enExample)
WO2020006349A1 (en) Therapeutic lung repair by inhalation of lung spheroid cell-secreted factors
AU2017277735A1 (en) Cbl-family inhibitor comprising a Cbl-family TKB domain binding peptide for the prevention or treatment of diseases
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
CN105358678A (zh) 治疗和/或预防1型糖尿病的方法和组合物
Yao et al. Radiation-triggerable bioreactors enable bioenergetic reprograming of cancer stem cell plasticity via targeted arginine metabolism disruption for augmented radio-immunotherapy
RU2010136988A (ru) Антигенсвязывающие полипептиды против дегенерации хряща

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2016 BY SPRUSON + FERGUSON

Effective date: 20150619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2017 BY DENNEMEYER + CO

Effective date: 20160622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2018 BY DENNEMEYER + CO

Effective date: 20170623

LAPS Patent lapsed